ZA200708026B - Anti-CTLA4 antibody and indolinone combination therapy for treatment of cancer - Google Patents

Anti-CTLA4 antibody and indolinone combination therapy for treatment of cancer

Info

Publication number
ZA200708026B
ZA200708026B ZA200708026A ZA200708026A ZA200708026B ZA 200708026 B ZA200708026 B ZA 200708026B ZA 200708026 A ZA200708026 A ZA 200708026A ZA 200708026 A ZA200708026 A ZA 200708026A ZA 200708026 B ZA200708026 B ZA 200708026B
Authority
ZA
South Africa
Prior art keywords
indolinone
cancer
treatment
combination therapy
ctla4 antibody
Prior art date
Application number
ZA200708026A
Other languages
English (en)
Inventor
Gomez-Navarro Jesus
Baum Charles Michael
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ZA200708026B publication Critical patent/ZA200708026B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ZA200708026A 2005-03-23 2007-09-18 Anti-CTLA4 antibody and indolinone combination therapy for treatment of cancer ZA200708026B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66465305P 2005-03-23 2005-03-23

Publications (1)

Publication Number Publication Date
ZA200708026B true ZA200708026B (en) 2008-11-26

Family

ID=36680342

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200708026A ZA200708026B (en) 2005-03-23 2007-09-18 Anti-CTLA4 antibody and indolinone combination therapy for treatment of cancer

Country Status (16)

Country Link
US (1) US20090074787A1 (ru)
EP (1) EP1863532A1 (ru)
JP (1) JP2006265245A (ru)
KR (1) KR20070104673A (ru)
CN (1) CN101146553A (ru)
AR (1) AR054237A1 (ru)
AU (1) AU2006227880A1 (ru)
BR (1) BRPI0607579A2 (ru)
CA (1) CA2602316A1 (ru)
IL (1) IL185491A0 (ru)
MX (1) MX2007011767A (ru)
NZ (1) NZ561138A (ru)
RU (1) RU2007135167A (ru)
TW (1) TW200700083A (ru)
WO (1) WO2006101692A1 (ru)
ZA (1) ZA200708026B (ru)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101267824A (zh) * 2005-09-20 2008-09-17 辉瑞产品公司 使用酪氨酸激酶抑制剂的治疗剂型和方法
WO2007113648A2 (en) * 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
EP2124998B8 (en) * 2006-12-27 2015-05-06 The Johns Hopkins University Methods for detecting inflammation and auto-immune diseases
WO2010014784A2 (en) * 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
DK2769737T3 (en) * 2009-07-20 2017-07-24 Bristol Myers Squibb Co COMBINATION OF ANTI-CTLA4 ANTIBODY WITH ETOPOSIDE FOR SYNERGISTIC TREATMENT OF PROLIFERATIVE DISEASES
BR112012008665A2 (pt) * 2009-10-12 2016-11-22 Pfizer tratamento de câncer
CA3113343A1 (en) 2010-06-03 2011-12-08 Pharmacyclics Llc Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of follicular lymphoma
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
US9107887B2 (en) 2011-03-10 2015-08-18 Provectus Pharmaceuticals, Inc. Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
MX359257B (es) 2012-05-04 2018-09-19 Pfizer Antígenos asociados a próstata y regímenes de inmunoterapia basados en vacuna.
SG11201407190TA (en) 2012-05-15 2014-12-30 Bristol Myers Squibb Co Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
EP3550031A1 (en) 2012-07-24 2019-10-09 Pharmacyclics, LLC Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
WO2014182761A1 (en) * 2013-05-09 2014-11-13 Mayo Foundation For Medical Education And Research Treating patients based on immune subtypes
GB201413665D0 (en) 2014-07-03 2014-09-17 Transimmune Ag And Yale University Method for obtaining globally activated monocytes
JP6245622B2 (ja) * 2014-08-07 2017-12-13 学校法人兵庫医科大学 Ｉｌ−１８と分子標的抗体とを併用する癌治療薬
ES2727137T3 (es) 2014-08-28 2019-10-14 Halozyme Inc Terapia combinada con una enzima de degradación de hialuronano y un inhibidor de puntos de control inmunitario
CA3203273A1 (en) 2014-10-14 2016-04-21 Halozyme, Inc. Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
CN108271359B (zh) * 2015-02-13 2021-11-09 索伦托药业有限公司 结合ctla4的抗体治疗剂
WO2016161347A1 (en) * 2015-04-03 2016-10-06 Pharmacyclics Llc Combinations for generating tumor-specific immunological memory
MX2017016931A (es) 2015-06-24 2018-09-26 Immodulon Therapeutics Ltd Inhibidor del punto de regulacion y un mycobaterium de celula entera para uso en la terapia del cancer.
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
EP3471753A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 and il-2 cytokines
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
JP7173993B2 (ja) * 2017-05-19 2022-11-17 ウーシー バイオロジクス（シャンハイ）カンパニー リミテッド 細胞傷害性ｔリンパ球関連タンパク質４（ｃｔｌａ－４）に対する新規モノクローナル抗体
WO2019148444A1 (en) * 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
CN112105343B (zh) * 2018-03-07 2024-07-30 辉瑞公司 抗-pd-1抗体组合物
WO2020014543A2 (en) 2018-07-11 2020-01-16 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
KR102371980B1 (ko) 2020-06-29 2022-03-08 인하대학교 산학협력단 췌장암 예방 또는 치료용 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5844095A (en) * 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5855887A (en) * 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) * 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) * 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
JP2001523958A (ja) * 1997-03-21 2001-11-27 ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド 免疫療法のｃｔｌａ−４結合ペプチド
US7109003B2 (en) * 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
EE05627B1 (et) * 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
ME00415B (me) * 2000-02-15 2011-10-10 Pharmacia & Upjohn Co Llc Pirol supstituisani 2-indol protein kinazni inhibitori
AR042586A1 (es) * 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
IL149701A0 (en) * 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
US6599902B2 (en) * 2001-05-30 2003-07-29 Sugen, Inc. 5-aralkysufonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
US6680306B2 (en) * 2001-06-21 2004-01-20 Glycogenesys, Inc. Method for enhancing the effectiveness of cancer therapies
EP1549678A4 (en) * 2002-09-30 2006-01-18 Pfizer Prod Inc HYBRIDOMAS THAT PRODUCE HIGH CONCENTRATIONS OF ANTIBODIES TO THE HUMAN SEQUENCE
AR042042A1 (es) * 2002-11-15 2005-06-08 Sugen Inc Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular
RU2319702C2 (ru) * 2003-10-02 2008-03-20 Фармация Энд Апджон Компани Ллс Негигроскопическая кристаллическая малеатная соль 5-[(z)-(5-фтор-2-оксо-1,2-дигидро-3h-индол-3-илиден)метил]-n-[(2s)-2-гидрокси-3-морфолин-4-илпропил]-2,4-диметил-1h-пиррол-3-карбоксамида, фармацевтическая композиция и способ лечения рака
US20050182122A1 (en) * 2003-11-20 2005-08-18 Bello Carlo L. Method of treating abnormal cell growth using indolinone compounds
BRPI0509274A (pt) * 2004-03-26 2007-09-04 Pfizer Prod Inc usos de anticorpos anti-ctla-4

Also Published As

Publication number Publication date
AU2006227880A1 (en) 2006-09-28
IL185491A0 (en) 2008-01-06
KR20070104673A (ko) 2007-10-26
CN101146553A (zh) 2008-03-19
US20090074787A1 (en) 2009-03-19
NZ561138A (en) 2009-06-26
MX2007011767A (es) 2007-10-18
EP1863532A1 (en) 2007-12-12
WO2006101692A1 (en) 2006-09-28
BRPI0607579A2 (pt) 2009-09-15
RU2007135167A (ru) 2009-03-27
TW200700083A (en) 2007-01-01
CA2602316A1 (en) 2006-09-28
AR054237A1 (es) 2007-06-13
JP2006265245A (ja) 2006-10-05

Similar Documents

Publication Publication Date Title
IL185491A0 (en) Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer
HUS1900030I1 (hu) Androgén receptor modulátorok a prosztatarák és androgén receptorral összefüggõ betegségek kezelésére
HK1204476A1 (en) Compounds and methods for treatment of cancer
IL225386A0 (en) Diagnosis and treatment of cancer using anti-ereg antibody
EP1811844A4 (en) METHOD FOR THE DIAGNOSIS AND TREATMENT OF CANCER
EP2050466A4 (en) DIAGNOSIS AND TREATMENT OF CANCER USING ANTI-DESMOGLEIN ANTIBODY-3
PL1874821T3 (pl) Kombinacja przeciwciał i glikokortykoidów do leczenia raka
IL187898A0 (en) Parp modulators and treatment of cancer
HK1164767A1 (en) Compounds and methods for the treatment of cancer
IL226363A0 (en) Compounds and methods for treating cancer
EP2231684A4 (en) COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER
GB0700281D0 (en) Methods and Means for the Treatment of Cancer